We then compared the effect of NT1721 on the cell viability with that of drugs currently used for AML treatment, i.e. the standard remission induction drug, cytarabine, and sorafenib, a TKI that has been used in clinical trials in patients harboring FLT3-ITD mutations [38]. The gene discussed is FLT3; the disease is acute myeloid leukemia.